Skip to content

Investor Relations


Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for urgent unmet medical needs. Our current focus is on the treatment of patients with pancreatic cancer. The initial product candidate is SBP-101, a polyamine metabolic inhibitor in clinical development for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.